Home » Stocks » COCP

Cocrystal Pharma, Inc. (COCP)

Stock Price: $1.08 USD -0.03 (-2.70%)
Updated May 13, 2021 1:55 PM EDT - Market open
Market Cap 83.62M
Revenue (ttm) 2.01M
Net Income (ttm) -9.65M
Shares Out 55.22M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.08
Previous Close $1.11
Change ($) -0.03
Change (%) -2.70%
Day's Open 1.13
Day's Range 1.08 - 1.14
Day's Volume 8,508,700
52-Week Range 0.76 - 3.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...

Other stocks mentioned: AGEN, ATOS, CDMO, OCGN, SIGA, SIOX
22 hours ago - InvestorPlace

BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

5 days ago - GlobeNewsWire

Nemaura Medical Inc. (NASDAQ: NMRD), iBio, Inc. (NYSE: IBIO) and Cocrystal Pharma, Inc. (NASDAQ: COCP) are among the healthcare movers Wednesday. Nemaura Rallies On Receipt of Orders: Nemaura, a medtech...

Other stocks mentioned: IBIO, NMRD
1 week ago - Benzinga

The trading in biotechnology company Cocrystal Pharma, Inc. (NASDAQ: COCP) is a good example of how inexperienced traders can lose a lot of money. What Happened: Cocrystal closed Tuesday at $2.14, a gai...

1 week ago - Benzinga

Cocrystal Pharma Inc (NASDAQ: COCP) has entered into an underwriting agreement with H.C. Wainwright & Co LLC, under which the underwriter has agreed to purchase 26 million shares at $1.54 per share.

1 week ago - Benzinga

BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

1 week ago - GlobeNewsWire

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday.

Other stocks mentioned: BLRX, CCXI
1 week ago - Benzinga

COCP stock is on the move this morning after announcing promising news about its Covid-19 antiviral treatments. Here's what to know.

1 week ago - InvestorPlace

Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 progra...

1 week ago - Benzinga

Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs

1 month ago - GlobeNewsWire

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antivir...

2 months ago - GlobeNewsWire

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antivira...

2 months ago - GlobeNewsWire

Cocrystal Pharma (COCP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

3 months ago - GlobeNewsWire

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, a...

Other stocks mentioned: DTIL
3 months ago - Benzinga

Program advances within the agreement's initial two-year timeframe

3 months ago - GlobeNewsWire

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

3 months ago - GlobeNewsWire

BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...

4 months ago - GlobeNewsWire

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

4 months ago - GlobeNewsWire

The stock price of Cocrystal Pharma, Inc. (NASDAQ: COCP) increased by 111.17% over the past week as it went from $0.90 per share on November 20 to $1.89 per share as of today. This is why it happened.

5 months ago - Pulse2

Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company. The post Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biot...

5 months ago - InvestorPlace

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

5 months ago - GlobeNewsWire

BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral th...

6 months ago - GlobeNewsWire

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

6 months ago - GlobeNewsWire

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain –

6 months ago - GlobeNewsWire

BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, D...

7 months ago - GlobeNewsWire

– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT –

8 months ago - GlobeNewsWire

BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivira...

8 months ago - GlobeNewsWire

BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivira...

8 months ago - GlobeNewsWire

BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivira...

8 months ago - GlobeNewsWire

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing –

9 months ago - GlobeNewsWire

– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication –

9 months ago - GlobeNewsWire

Markets are down today, pretty much from the get-go. As investors become increasingly concerned with the worsening coronavirus cases, it's become clear that a sell-off is imminent.

Other stocks mentioned: AMRS, BKYI, MRAM, OSBC
10 months ago - Forbes

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Other stocks mentioned: BKYI, EYES, EYPT, REPH
10 months ago - Forbes

With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio with or bet...

Other stocks mentioned: BLNK, ECOR, TTPH
10 months ago - Forbes

We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.

Other stocks mentioned: ECOR, INSE, KMPH
11 months ago - Forbes

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified several top ...

Other stocks mentioned: BLNK, DMTK, TTPH
11 months ago - Forbes

- Company has sufficient capital to advance pipeline and fund operations through 2021 -

11 months ago - GlobeNewsWire

– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program –

1 year ago - GlobeNewsWire

- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program -

1 year ago - GlobeNewsWire

- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals -

1 year ago - GlobeNewsWire

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

1 year ago - GlobeNewsWire

BOTHELL, WA, March 30, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivi...

1 year ago - GlobeNewsWire

BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral ...

1 year ago - GlobeNewsWire

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points...

Other stocks mentioned: GILD, GSK, INO, JNJ, MRNA, NNVC, NVAX ...
1 year ago - Benzinga

BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral ...

1 year ago - GlobeNewsWire

The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and Russia.

Other stocks mentioned: AIM, SPEX
1 year ago - Benzinga

BOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivir...

1 year ago - GlobeNewsWire

BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC.  (NASDAQ : COCP ) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel an...

1 year ago - GlobeNewsWire

BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC.  ( NASDAQ: COCP ) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antivir...

1 year ago - GlobeNewsWire

About COCP

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for... [Read more...]

Industry
Biotechnology
CEO
Gary Wilcox
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
COCP
Full Company Profile

Financial Performance

In 2020, COCP's revenue was $2.01 million, a decrease of -69.32% compared to the previous year's $6.56 million. Losses were -$9.65 million, -79.97% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for COCP stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 316.67% from the latest price.

Price Target
$4.50
(316.67% upside)
Analyst Consensus: Buy